ARTICLE SUMMARY:
As the lone player in neuromodulation for overactive bladder disease, Medtronic has carved out $500 million in revenues. Axonics aims to come in with an improved product, and it has a head start, thanks to the Alfred Mann Foundation.
After renal denervation company Vessix Vascular was sold to Boston Scientific Corp. in late 2012, the start-up’s former CEO, Raymond Cohen, was busy serving on corporate boards when he was approached by John Petrovich, the head of business development for the Alfred Mann Foundation (AMF).
